$EXEL · EXELIXIS, INC. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for EXELIXIS, INC. ($EXEL) from October 29, 2026 through October 29, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$EXEL 10-Q — EXELIXIS, INC.
Exelixis combines double-digit revenue growth, expanding margins, and aggressive capital return — $1B in buybacks over nine months — while advancing a pipeline catalyst in zanza…
$EXEL 8-K — EXELIXIS, INC.
Exelixis delivered a clean beat-and-hold quarter while the zanzalintinib pipeline advances toward two major Q1 2027 catalysts: the CRC PDUFA and STELLAR-304 topline data.